Latest Clinical Trials News

Page 4 of 140
Invex Therapeutics has paired its proposed acquisition of Rekover Therapeutics with a $10 million equity raising to fund a Phase 2a multiple sclerosis study and its existing Exenatide programs. The biotech ended September with A$3.59 million in cash, with shareholder approval still required for the larger part of the transaction.
Ada Torres
Ada Torres
30 Oct 2026
Recce Pharmaceuticals has cleared an active-comparator design for its pivotal Australian diabetic foot infection trial while an independent review of Indonesian Phase 3 data approaches. The biotech ended the quarter with A$1.04 million in cash, alongside expected tax rebates and unused financing facilities.
Victor Sage
Victor Sage
30 Oct 2026
Alterity Therapeutics says it has begun operational preparations for a Phase 3 ATH434 trial after FDA minutes confirmed the proposed design and registrational pathway in Multiple System Atrophy. The company ended September with A$41.3 million in cash, while a new US patent extends protection for ATH434 to 2045.
Ada Torres
Ada Torres
30 Oct 2026
Paradigm Biopharmaceuticals’ pivotal knee osteoarthritis trial fell below its pre-specified continuation threshold, leaving the ASX-listed biotech in voluntary administration with A$4.33 million in cash. Administrators now have up to three months to assess restructuring options, clinical data and the company’s future.
Victor Sage
Victor Sage
30 Oct 2026
Epiminder has enrolled its 100th patient in the DETECT US epilepsy study ahead of schedule, while maintaining A$65.1 million in cash and no borrowings. The company says those reserves can fund clinical development and commercialisation work well into 2028.
Victor Sage
Victor Sage
30 Oct 2026
Imugene reported an 86% overall response rate in its BTK inhibitor combination cohort, but ended September with only 0.70 quarters of estimated funding at the reported cash burn. The biotechnology company is assessing further capital sources while navigating a leadership transition and convertible note obligations.
Ada Torres
Ada Torres
30 Oct 2026
Ceretas has enrolled the first patient in its Phase 2 CERE-CALM Alzheimer’s trial after completing its first quarter as an ASX-listed company. The medical technology group ended September with $7.1 million in cash, while a device milestone unlocked a further $692,578 in non-dilutive funding.
Victor Sage
Victor Sage
30 Oct 2026
OncoSil Medical enters FY27 with FDA approval for its cancer device, rising quarterly revenue and fresh institutional funding, but its U.S. opportunity still depends on reimbursement and a tightly controlled initial rollout. Cash rose to A$8.7 million after the capital raise, while operating cash use remained substantial.
Victor Sage
Victor Sage
30 Oct 2026
Nexalis Therapeutics ended September with $371,000 in cash, equivalent to just 0.9 quarters of funding at its recent operating burn. The company has settled its dispute with Linlithgow Family Office, but its clinical programs remain paused while it pursues R&D tax funding and a new capital raise.
Ada Torres
Ada Torres
30 Oct 2026
Chimeric Therapeutics has stopped enrolment and dosing in its CHM-2101 CAR-T trial after a safety review found the highest dose unsafe. With $1.35 million in cash, suspended securities and uncertain creditor negotiations, the company is now pursuing a possible recapitalisation while preserving a preclinical CDH17 pathway.
Ada Torres
Ada Torres
29 Oct 2026
Vectus Biosystems has secured FDA acceptance of a pre-IND Type B meeting for VB0004, a key regulatory step for its idiopathic pulmonary fibrosis programme. The biotech ended September with $410,000 in cash and reported estimated funding for just 1.33 quarters of operations.
Ada Torres
Ada Torres
29 Oct 2026
Tissue Repair has increased its US Phase III chronic wound trial to approximately 112 randomised patients while shifting focus towards an April 2027 FDA 510(k) submission. The company also reported $4.74 million in cash, Australian availability of all three TR Pro+ formats and a planned $1 million share buy-back.
Ada Torres
Ada Torres
29 Oct 2026

Browse the archive

Full archive